Edition:
United States

ARIAD Pharmaceuticals Inc (ARIA.O)

ARIA.O on Nasdaq

8.11USD
22 Jul 2016
Change (% chg)

$0.13 (+1.63%)
Prev Close
$7.98
Open
$7.97
Day's High
$8.24
Day's Low
$7.89
Volume
6,136,555
Avg. Vol
4,166,035
52-wk High
$10.07
52-wk Low
$4.37

Latest Key Developments (Source: Significant Developments)

Ariad Pharmaceuticals completes strategic review, reaffirms 2016 outlook
Friday, 17 Jun 2016 12:33pm EDT 

Ariad Pharmaceuticals Inc : Reaffirmed 2016 financial guidance . Outcomes of strategic review includes significant reduction in company's expense base . Announces changes to its executive leadership team and board of directors as part of strategic review . FY 2016 earnings per share view $-0.60, revenue view $214.8 million -- Thomson Reuters I/B/E/S .Ariad completes strategic review and announces plans for growth.  Full Article

Ariad initiates submission of NDA for Brigatinib to FDA ahead of plan
Friday, 17 Jun 2016 07:35am EDT 

Ariad Pharmaceuticals Inc : Rolling NDA submission is expected to be complete in Q3 of 2016. . "We are ahead of our previously announced schedule for initiating submission of our Brigatinib nda to FDA" . Seeking accelerated approval for Brigatinib from FDA and plans to request a priority review of application .Ariad initiates submission of new drug application for Brigatinib to the U.S. Food And Drug Administration ahead of plan.  Full Article

Ariad provides long-term data on cancer drug, Iclusig
Monday, 13 Jun 2016 07:35am EDT 

Ariad Pharmaceuticals Inc : Overall survival at four years is estimated to be 77 percent . 82 percent of cp-cml patients who achieved mcyr are estimated to remain in mcyr at four years . 96 percent of cp-cml patients who underwent ponatinib dose reductions while in response maintained their responses at four year timepoint . Patients treated with iclusig continued to demonstrate anti-leukemic activity with a median follow-up of 4.0 years for cp-cml .Term safety and efficacy data of ponatinib from phase 2 pace clinical trial.  Full Article

Incyte Corp amends buy-in license deal entered into by Ariad Pharmaceuticals
Wednesday, 1 Jun 2016 04:06pm EDT 

Incyte Corp : On june 1, 2016, amended buy-in license deal entered into by ariad pharmaceuticals, ariad pharmaceuticals (europe) s.a.r.l. & co . Under terms, incyte europe granted exclusive license to develop & commercialize iclusig in european union and 22 other countries - sec filing .Ariad will be eligible to receive from incyte europe tiered royalties of between 32% and 50% on net sales of iclusig in territory.  Full Article

Ariad Pharmaceuticals announces pricing, reimbursement for iclusig in France
Thursday, 19 May 2016 07:35am EDT 

Ariad Pharmaceuticals Inc : Ariad announces pricing and reimbursement for iclusig in France . Ariad will record net product revenue related to cumulative shipments in France of approximately $25 million in q2 of 2016 .Negotiations with economic committee on health care products in France regarding pricing and reimbursement for iclusig have now concluded.  Full Article

Ariad Pharmaceuticals posts Q1 loss per share $0.28
Tuesday, 10 May 2016 07:35am EDT 

Ariad Pharmaceuticals Inc : Ariad reports first quarter 2016 financial results and progress on strategic review . Q1 GAAP loss per share $0.28 . Q1 non-GAAP loss per share $0.23 . Q1 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S . Qtrly total revenue $35.6 million versus $24 million . On track to complete strategic review this quarter . 2016 global Iclusig net product and royalty revenues are expected to be in range of $170 million to $180 million . Sees 2016 $175 million to $180 million for research and development expense . Restructuring charge expenses of $2.9 million for q1 , associated with employee workforce reductions of approximately 90 positions . Following anticipated closing of deal with Incyte, we are revising our product revenue guidance for 2016 . 2016 expense guidance reflects a reduction in expenses of about $30 million from planned divesture of European business to Incyte .Cash position at December 31, 2016 is expected to be in range of $280 million to $290 million.  Full Article

ARIAD Pharmaceuticals announces reduction in workforce as part of ongoing company-wide strategic review
Tuesday, 29 Mar 2016 12:51pm EDT 

ARIAD Pharmaceuticals:Says that it is reducing approximately 25 percent of its headquarter positions.Says reduction includes approximately 90 positions in the U.S. and Europe.Says reduction in workforce is one of five key areas of ARIAD's ongoing strategic review.  Full Article

ARIAD Pharmaceuticals, Inc announces leadership change
Friday, 11 Mar 2016 07:35am EST 

ARIAD Pharmaceuticals, Inc:Announces appointment of manmeet s. soni as chief financial officer.Says soni will succeed edward m. Fitzgerald.Soni most recently served as chief financial officer of pharmacyclics, inc.  Full Article

Ariad Pharmaceuticals Inc announces FDA clearance to begin clinical development of AP32788
Monday, 1 Feb 2016 07:35am EST 

Ariad Pharmaceuticals Inc:Announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's Investigational New Drug (IND) application for AP32788.  Full Article

ARIAD Pharmaceuticals Inc names Paris Panayiotopoulos as Its President and Chief Executive Officer
Friday, 18 Dec 2015 07:35am EST 

ARIAD Pharmaceuticals Inc:Announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), effective January 1, 2016.Panayiotopoulos will succeed Harvey J. Berger, M.D., ARIAD's founder, chairman and CEO.  Full Article

BRIEF-Ariad Pharmaceuticals completes strategic review, reaffirms 2016 outlook

* Outcomes of strategic review includes significant reduction in company's expense base